These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 19804966)

  • 1. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
    Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?
    Otto SJ; Schröder FH; de Koning HJ
    J Med Screen; 2004; 11(2):89-92. PubMed ID: 15153324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
    Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
    Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
    Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.